Using Tissue Polypeptide Antigen to Diagnose Pancreatic Cancer
Author Information
Author(s): A. Panucci, C. Fabris, G. Del Favero, D. Basso, L. Marchioro, A. Piccoli, A. Burlina, R. Naccarato
Primary Institution: Istituto di Medicina Interna, Universita degli Studi di Padova
Hypothesis
Can Tissue Polypeptide Antigen (TPA) effectively distinguish pancreatic cancer from other conditions?
Conclusion
The study found that TPA levels are significantly higher in pancreatic cancer patients compared to those with chronic pancreatitis and other gastrointestinal diseases.
Supporting Evidence
- TPA levels were significantly higher in pancreatic cancer patients compared to controls.
- Only 2 out of 24 chronic pancreatitis patients had abnormal TPA levels.
- The sensitivity of TPA for diagnosing pancreatic cancer was 96.4%.
- TPA levels correlated with liver function tests in extra-pancreatic diseases.
Takeaway
Doctors can use a blood test for TPA to help tell if someone has pancreatic cancer, which is important for getting the right treatment.
Methodology
Serum TPA was measured using a radioimmunoassay (RIA) procedure, and statistical analysis was performed using ANOVA and other tests.
Limitations
The study may not account for all possible conditions that could affect TPA levels.
Participant Demographics
The study included 29 healthy controls, 28 pancreatic cancer patients, 24 with chronic pancreatitis, and 25 with other gastrointestinal diseases.
Statistical Information
P-Value
P=0.0000
Statistical Significance
p<0.0005
Want to read the original?
Access the complete publication on the publisher's website